Verastem Inc.

09/19/2021 | Press release | Distributed by Public on 09/19/2021 09:56

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response[...]